159 related articles for article (PubMed ID: 30099379)
1. Safety of 5914 intravitreal ziv-aflibercept injections.
Singh SR; Stewart MW; Chattannavar G; Ashraf M; Souka A; ElDardeery M; Wadhwa N; Sarvaiya C; Mansour AM; Marashi A; Ramchandani S; Braimah IZ; Jabbarpoor Bonyadi MH; Ramezani A; Soheilian M; de Oliveira Dias JR; de Andrade GC; Maia A; Rodrigues EB; Farah ME; Banker A; Chhablani J;
Br J Ophthalmol; 2019 Jun; 103(6):805-810. PubMed ID: 30099379
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal Ziv-Aflibercept : Safety Analysis in Eyes Receiving More Than Ten Intravitreal Injections.
Singh SR; Chattannavar G; Ayachit A; Pimentel MC; Alfaro A; Tiwari S; Heranjal A; Subramanyam A; Braimah IZ; Dhami A; Sachdev P; Mansour A; Chhablani J
Semin Ophthalmol; 2020 Jan; 35(1):2-6. PubMed ID: 31690175
[No Abstract] [Full Text] [Related]
3. Two-year outcomes of intravitreal ziv-aflibercept.
Mansour AM; Ashraf M; Charbaji A; Younis MH; Souka AA; Dogra A; Mansour HA; Chhablani J;
Br J Ophthalmol; 2018 Oct; 102(10):1387-1390. PubMed ID: 29317400
[TBL] [Abstract][Full Text] [Related]
4. One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration.
Braimah IZ; Agarwal K; Mansour A; Chhablani J;
Br J Ophthalmol; 2018 Jan; 102(1):91-96. PubMed ID: 28596286
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab versus ziv-aflibercept in branch retinal vein occlusion.
Braimah IZ; Singh SR; Uplanchiwar B; Mansour AM; Chhablani J
Indian J Ophthalmol; 2019 Jul; 67(7):1109-1113. PubMed ID: 31238422
[TBL] [Abstract][Full Text] [Related]
6. Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy.
Singh SR; Sahoo NK; Goud NR; Chhablani J
Indian J Ophthalmol; 2019 Jul; 67(7):1114-1118. PubMed ID: 31238423
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal Ziv-Aflibercept: A Comprehensive Review.
Barmas-Alamdari D; D'Souza HS; Kapoor KG; Wagner AL
Semin Ophthalmol; 2019; 34(6):420-435. PubMed ID: 31314638
[No Abstract] [Full Text] [Related]
8. Safety and Efficacy of Ziv-Aflibercept in the Treatment of Refractory Diabetic Macular Edema.
Ashraf M; Kayal HE; Souka AAR
Ophthalmic Surg Lasers Imaging Retina; 2017 May; 48(5):399-405. PubMed ID: 28499051
[TBL] [Abstract][Full Text] [Related]
9. Three-month outcome of ziv-aflibercept for exudative age-related macular degeneration.
Mansour AM; Chhablani J; Antonios RS; Yogi R; Younis MH; Dakroub R; Chahine H
Br J Ophthalmol; 2016 Dec; 100(12):1629-1633. PubMed ID: 27030277
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal ziv-aflibercept for the treatment of choroidal neovascularisation associated with conditions other than age-related macular degeneration.
Braimah IZ; Stewart M; Videkar C; Dedhia CJ; Chhablani J;
Br J Ophthalmol; 2017 Sep; 101(9):1201-1205. PubMed ID: 28119292
[TBL] [Abstract][Full Text] [Related]
11. CLINICAL AND ELECTROPHYSIOLOGICAL EVALUATION AFTER INTRAVITREAL ZIV-AFLIBERCEPT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
de Oliveira Dias JR; de Andrade GC; Kniggendorf VF; Novais EA; Maia A; Meyer C; Watanabe SES; Farah ME; Rodrigues EB
Retina; 2017 Aug; 37(8):1499-1507. PubMed ID: 27798520
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of ziv-aflibercept in retinal diseases.
Mansour AM; Ashraf M; Dedhia CJ; Charbaji A; Souka AAR; Chhablani J
Br J Ophthalmol; 2017 Oct; 101(10):1374-1376. PubMed ID: 28270485
[TBL] [Abstract][Full Text] [Related]
13. Safety of intravitreal ziv-aflibercept in choroido-retinal vascular diseases: A randomised double-blind intervention study.
Braimah IZ; Kenu E; Amissah-Arthur KN; Akafo S; Kwarteng KO; Amoaku WM
PLoS One; 2019; 14(10):e0223944. PubMed ID: 31647843
[TBL] [Abstract][Full Text] [Related]
14. Three-month outcome of intravitreal ziv-aflibercept in eyes with diabetic macular oedema.
Mansour AM; Dedhia C; Chhablani J
Br J Ophthalmol; 2017 Feb; 101(2):166-169. PubMed ID: 27190127
[TBL] [Abstract][Full Text] [Related]
15. EFFICACY OF INTRAVITREAL AFLIBERCEPT IN MACULAR TELANGIECTASIA TYPE 1 IS LINKED TO THE OCULAR ANGIOGENIC PROFILE.
Kowalczuk L; Matet A; Dirani A; Daruich A; Ambresin A; Mantel I; Spaide RF; Turck N; Behar-Cohen F
Retina; 2017 Dec; 37(12):2226-2237. PubMed ID: 28002269
[TBL] [Abstract][Full Text] [Related]
16. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
[TBL] [Abstract][Full Text] [Related]
17. One-Year Results of a Trial Comparing 2 Doses of Intravitreal Ziv-aflibercept versus Bevacizumab for Treatment of Diabetic Macular Edema.
Jabbarpoor Bonyadi MH; Baghi A; Ramezani A; Yaseri M; Soheilian M
Ophthalmol Retina; 2018 May; 2(5):428-440. PubMed ID: 31047323
[TBL] [Abstract][Full Text] [Related]
18. Safety and Bioavailability of Complete and Half-Dose Intravitreal Ziv-Aflibercept in an Experimental Model: Contralateral Eye Study.
Lashay A; Delrish E; Ashrafi E; Movassat M; Asadi-Amoli F; Dinarvand R; Abrishami M
Ophthalmic Surg Lasers Imaging Retina; 2019 Dec; 50(12):785-790. PubMed ID: 31877224
[TBL] [Abstract][Full Text] [Related]
19. SHORT-TERM SAFETY OF 2 MG INTRAVITREAL ZIV-AFLIBERCEPT.
Chhablani J; Dedhia CJ; Peguda HK; Stewart M
Retina; 2017 Oct; 37(10):1859-1865. PubMed ID: 28060148
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal Aflibercept for Retinal Angiomatous Proliferation: Results of a Prospective Case Series at 96 Weeks.
Browning AC; O'Brien JM; Vieira RV; Gupta R; Nenova K
Ophthalmologica; 2019; 242(4):239-246. PubMed ID: 31163436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
